Daniel J Diekema

List of Publications by Year in Descending Order

263 papers	25,087 citations	86 h-index	152 g-index
265 ext. papers	27,729 ext. citations	7.7 avg, IF	7.04 L-index

#	Paper	IF	Citations
263	Insertion site inflammation was associated with central-line-associated bloodstream infections at a tertiary-care center, 2015-2018. *Infection Control and Hospital Epidemiology*, **2021**, 42, 348-350	2	2
262	Successful termination of an outbreak of infections associated with contaminated heater-cooler devices. *Infection Control and Hospital Epidemiology*, **2021**, 42, 471-473	2	0
261	A primer on data visualization in infection prevention and antimicrobial stewardship. *Infection Control and Hospital Epidemiology*, **2020**, 41, 948-957	2	3
260	A randomized control trial evaluating efficacy of antimicrobial impregnated hospital privacy curtains in an intensive care setting. *American Journal of Infection Control*, **2020**, 48, 862-868	3.8	4
259	Impact of Infectious Disease Consultation in Patients With Candidemia: A Retrospective Study, Systematic Literature Review, and Meta-analysis. *Open Forum Infectious Diseases*, **2020**, 7, ofaa270	1	8
258	Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017). *Diagnostic Microbiology and Infectious Disease*, **2020**, 97, 115016	2.9	9
257	Moving Personal Protective Equipment Into the Community: Face Shields and Containment of COVID-19. *JAMA - Journal of the American Medical Association*, **2020**, 323, 2252-2253	27.4	74
256	Contamination of health-care workersThands with Escherichia coli and Klebsiella species after routine patient care: a prospective observational study. *Clinical Microbiology and Infection*, **2020**, 26, 760-766	9.5	1
255	Incidence and Outcomes Associated With Clostridium difficile Infections: A Systematic Review and Meta-analysis. *JAMA Network Open*, **2020**, 3, e1917597	10.4	32
254	Long-term follow-up of post-cardiac surgery Mycobacterium chimaera infections: A 5-center case series. *Journal of Infection*, **2020**, 80, 197-203	18.9	4
253	Reduction in abdominal hysterectomy surgical site infection rates after the addition of anaerobic antimicrobial prophylaxis. *Infection Control and Hospital Epidemiology*, **2020**, 41, 1469-1471	2	
252	Negative pressure face shield for flexible laryngoscopy in the COVID-19 era. *Laryngoscope Investigative Otolaryngology*, **2020**, 5, 718-726	2.8	8
251	Administrative coding methods impact surgical site infection rates. *Infection Control and Hospital Epidemiology*, **2020**, 41, 1461-1463	2	
250	Genomic Analysis of Cardiac Surgery-Associated Mycobacterium chimaera Infections, United States. *Emerging Infectious Diseases*, **2019**, 25, 559-563	10.2	18
249	Impact of expanded influenza post-exposure prophylaxis on healthcare worker absenteeism at a tertiary care center during the 2017-2018 season. *Infection Control and Hospital Epidemiology*, **2019**, 40, 260-261	2	1
248	Comparing brief, covert, directly observed hand hygiene compliance monitoring to standard methods: A multicenter cohort study. *American Journal of Infection Control*, **2019**, 47, 346-348	3.8	5
247	Research Agenda for Microbiome Based Research for Multidrug-resistant Organism Prevention in the Veterans Health Administration System. *Infection Control and Hospital Epidemiology*, **2018**, 39, 202-209	2	1

246	Impact of 2018 Changes in National Healthcare Safety Network Surveillance for Clostridium difficile Laboratory-Identified Event Reporting. *Infection Control and Hospital Epidemiology*, **2018**, 39, 886-888	2	5
245	Discontinuing contact precautions for multidrug-resistant organisms: A systematic literature review and meta-analysis. *American Journal of Infection Control*, **2018**, 46, 333-340	3.8	34
244	Infection prevention strategies for procedures performed outside operating rooms: A conceptual integrated model. *American Journal of Infection Control*, **2018**, 46, 94-96	3.8	2
243	Failure of Risk-Adjustment by Test Method for C. difficile Laboratory-Identified Event Reporting. *Infection Control and Hospital Epidemiology*, **2017**, 38, 109-111	2	26
242	Rising Stakes for Health Care-Associated Infection Prevention: Implications for the Clinical Microbiology Laboratory. *Journal of Clinical Microbiology*, **2017**, 55, 996-1001	9.7	15
241	Mycobacterium chimaera Infections Associated With Contaminated Heater-Cooler Devices for Cardiac Surgery: Outbreak Management. *Clinical Infectious Diseases*, **2017**, 65, 669-674	11.6	36
240	Mycobacterium chimaera Outbreak Associated With Heater-Cooler Devices: Piecing the Puzzle Together. *Infection Control and Hospital Epidemiology*, **2017**, 38, 103-108	2	53
239	Association of Evidence-Based Care Processes With Mortality in Staphylococcus aureus Bacteremia at Veterans Health Administration Hospitals, 2003-2014. *JAMA Internal Medicine*, **2017**, 177, 1489-1497	11.5	59
238	Diagnostic Stewardship-Leveraging the Laboratory to Improve Antimicrobial Use. *JAMA - Journal of the American Medical Association*, **2017**, 318, 607-608	27.4	115
237	Incidence of Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella Infections in the United States: A Systematic Literature Review. *Infection Control and Hospital Epidemiology*, **2017**, 38, 1209-1215	2	86
236	Investigation of a Candida guilliermondii Pseudo-outbreak Reveals a Novel Source of Laboratory Contamination. *Journal of Clinical Microbiology*, **2017**, 55, 1080-1089	9.7	0
235	Detection and Prevalence of Penicillin-Susceptible Staphylococcus aureus in the United States in 2013. *Journal of Clinical Microbiology*, **2016**, 54, 812-4	9.7	23
234	Multilaboratory Evaluation of In Vitro Antifungal Susceptibility Testing of Dermatophytes for ME1111. *Journal of Clinical Microbiology*, **2016**, 54, 662-5	9.7	3
233	Increased Mortality Rates Associated with Staphylococcus aureus and Influenza Co-infection, Maryland and Iowa, USA(1). *Emerging Infectious Diseases*, **2016**, 22, 1253-6	10.2	22
232	Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1759-66	5.9	4
231	Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. *Clinical Infectious Diseases*, **2015**, 61, 361-7	11.6	134
230	Lessons learned from hospital Ebola preparation. *Infection Control and Hospital Epidemiology*, **2015**, 36, 627-31	2	27
229	Association of a bundled intervention with surgical site infections among patients undergoing cardiac, hip, or knee surgery. *JAMA - Journal of the American Medical Association*, **2015**, 313, 2162-71	27.4	183

228	Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 740-5	5.9	30
227	Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 916-22	5.9	35
226	Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 1748-54	5.1	187
225	Concordance of nasal and diabetic foot ulcer staphylococcal colonization. *Diagnostic Microbiology and Infectious Disease*, **2014**, 79, 85-9	2.9	12
224	Continued emergence of USA300 methicillin-resistant Staphylococcus aureus in the United States: results from a nationwide surveillance study. *Infection Control and Hospital Epidemiology*, **2014**, 35, 285-92	3	112
223	Multicenter evaluation of the new Vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole. *Journal of Clinical Microbiology*, **2014**, 52, 2126-30	9.7	19
222	Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria. *Journal of Clinical Microbiology*, **2014**, 52, 108-14	9.7	42
221	Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6484-9	5.9	110
220	Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria. *Journal of Clinical Microbiology*, **2014**, 52, 3223-9	9.7	41
219	Methicillin-resistant Staphylococcus aureus prevention practices in hospitals throughout a rural state. *American Journal of Infection Control*, **2014**, 42, 868-73	3.8	3
218	Candidemia surveillance in Iowa: emergence of echinocandin resistance. *Diagnostic Microbiology and Infectious Disease*, **2014**, 79, 205-8	2.9	38
217	Antibacterial properties of the CFTR potentiator ivacaftor. *Journal of Cystic Fibrosis*, **2014**, 13, 515-9	4.1	60
216	Phaeoacremonium parasiticum phaeohyphomycosis in a patient with systemic lupus erythematosus treated successfully with surgical debridement and voriconazole: A case report and review of the literature. *IDCases*, **2014**, 1, 84-8	2	0
215	Ebola fever: reconciling planning with risk in U.S. hospitals. *Annals of Internal Medicine*, **2014**, 161, 751-2	8	13
214	Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 577-80	5.9	59
213	Reconsidering isolation precautions for endemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. *JAMA - Journal of the American Medical Association*, **2014**, 312, 1395-6	27.4	28
212	Ebola virus disease and the need for new personal protective equipment. *JAMA - Journal of the American Medical Association*, **2014**, 312, 2495-6	27.4	30
211	Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. *PLoS ONE*, **2014**, 9, e101510	3.7	257

210	Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values. *Diagnostic Microbiology and Infectious Disease*, **2013**, 77, 37-40	2.9	29
209	Rapid detection of antibiotic-resistant organism carriage for infection prevention. *Clinical Infectious Diseases*, **2013**, 56, 1614-20	11.6	48
208	Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). *Emerging Infectious Diseases*, **2013**, 19, 1074-83	10.2	162
207	Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5642-8	5.9	47
206	Chlorhexidine and mupirocin susceptibilities of methicillin-resistant staphylococcus aureus from colonized nursing home residents. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 552-8	5.9	59
205	Developing a new, national approach to surveillance for ventilator-associated events. *American Journal of Critical Care*, **2013**, 22, 469-73	1.7	25
204	Evaluation of pneumococcal serotyping by multiplex PCR and quellung reactions. *Journal of Clinical Microbiology*, **2013**, 51, 4193-5	9.7	19
203	Long-term risk for readmission, methicillin-resistant Staphylococcus aureus (MRSA) infection, and death among MRSA-colonized veterans. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1169-72	5.9	21
202	Developing a new, national approach to surveillance for ventilator-associated events: executive summary. *Clinical Infectious Diseases*, **2013**, 57, 1742-6	11.6	36
201	Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs. *Journal of Clinical Microbiology*, **2013**, 51, 117-24	9.7	79
200	Contributions of Aspergillus fumigatus ATP-binding cassette transporter proteins to drug resistance and virulence. *Eukaryotic Cell*, **2013**, 12, 1619-28		56
199	Public reporting of health care-associated surveillance data: recommendations from the healthcare infection control practices advisory committee. *Annals of Internal Medicine*, **2013**, 159, 631-5	8	44
198	Seasonality of staphylococcal infections. *Clinical Microbiology and Infection*, **2012**, 18, 927-33	9.5	81
197	Evaluation of postprescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention. *Infection Control and Hospital Epidemiology*, **2012**, 33, 374-80	2	63
196	Prevalence, antibiotic resistance and molecular characterisation of Staphylococcus aureus in pigs at agricultural fairs in the USA. *Veterinary Record*, **2012**, 170, 495	0.9	24
195	Bacterial contamination of an automated pharmacy robot used for intravenous medication preparation. *Infection Control and Hospital Epidemiology*, **2012**, 33, 517-20	2	3
194	Novel hospital curtains with antimicrobial properties: a randomized, controlled trial. *Infection Control and Hospital Epidemiology*, **2012**, 33, 1081-5	2	37
193	The epidemiology of methicillin-resistant Staphylococcus aureus on a burn trauma unit. *Infection Control and Hospital Epidemiology*, **2012**, 33, 1118-25	2	7

192	The changing epidemiology of healthcare-associated candidemia over three decades. *Diagnostic Microbiology and Infectious Disease*, **2012**, 73, 45-8	2.9	234
191	Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. *Diagnostic Microbiology and Infectious Disease*, **2012**, 73, 365-8	2.9	53
190	Hospital privacy curtains are frequently and rapidly contaminated with potentially pathogenic bacteria. *American Journal of Infection Control*, **2012**, 40, 904-6	3.8	53
189	Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance) registry, 2004-2008. *Diagnostic Microbiology and Infectious Disease*, **2012**, 74, 323-31	2.9	271
188	Antimicrobial therapy for bloodstream infection due to methicillin-susceptible Staphylococcus aureus in an era of increasing methicillin resistance: opportunities for antimicrobial stewardship. *Annals of Pharmacotherapy*, **2012**, 46, 904-5	2.9	5
187	In vitro activity of ceftaroline against clinical isolates of Streptococcus pneumoniae recovered in 43 U.S. medical centers during 2010-2011. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 3406-8	5.9	6
186	Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. *Journal of Clinical Microbiology*, **2012**, 50, 2040-6	9.7	98
185	Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. *Journal of Clinical Microbiology*, **2012**, 50, 2846-56	9.7	323
184	Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 352-7	5.9	68
183	Diagnosing and reporting of central line-associated bloodstream infections. *Infection Control and Hospital Epidemiology*, **2012**, 33, 875-82	2	29
182	Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 5875-82	5.9	36
181	Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. *Diagnostic Microbiology and Infectious Disease*, **2011**, 70, 330-43	2.9	106
180	Plasmid-borne vga(A)-encoding gene in methicillin-resistant Staphylococcus aureus ST398 recovered from swine and a swine farmer in the United States. *Diagnostic Microbiology and Infectious Disease*, **2011**, 71, 177-80	2.9	16
179	Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. *Diagnostic Microbiology and Infectious Disease*, **2011**, 71, 252-9	2.9	51
178	Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. *Drug Resistance Updates*, **2011**, 14, 164-76	23.2	265
177	Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins. *Current Fungal Infection Reports*, **2011**, 5, 120-127	1.4	3
176	Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 4465-8	5.9	191
175	Current practice in Staphylococcus aureus screening and decolonization. *Infection Control and Hospital Epidemiology*, **2011**, 32, 1042-4	2	22

174	Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates. *Journal of Clinical Microbiology*, **2011**, 49, 1110-2	9.7	28
173	Methicillin-resistant Staphylococcus aureus in pork production shower facilities. *Applied and Environmental Microbiology*, **2011**, 77, 696-8	4.8	14
172	Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States. *Journal of Clinical Microbiology*, **2011**, 49, 4203-7	9.7	45
171	Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. *Journal of Clinical Microbiology*, **2011**, 49, 1765-71	9.7	25
170	Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. *Journal of Clinical Microbiology*, **2011**, 49, 586-90	9.7	75
169	Clinical significance of positive cranial bone flap cultures and associated risk of surgical site infection after craniotomies or craniectomies. *Journal of Neurosurgery*, **2011**, 114, 1746-54	3.2	44
168	Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program. *Journal of Clinical Microbiology*, **2011**, 49, 1274-9	9.7	25
167	Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 4154-60	5.9	60
166	Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 1543-8	5.9	29
165	Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. *Journal of Clinical Microbiology*, **2011**, 49, 630-7	9.7	54
164	Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. *Journal of Clinical Microbiology*, **2011**, 49, 3800-4	9.7	55
163	Prevalence and genetic relatedness of methicillin-susceptible Staphylococcus aureus isolates detected by the Xpert MRSA nasal assay. *Journal of Clinical Microbiology*, **2011**, 49, 2996-9	9.7	28
162	Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. *Journal of Clinical Microbiology*, **2011**, 49, 845-50	9.7	50
161	Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. *Journal of Clinical Microbiology*, **2011**, 49, 624-9	9.7	48
160	Decline in invasive MRSA infection: where to go from here?. *JAMA - Journal of the American Medical Association*, **2010**, 304, 687-9	27.4	17
159	Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. *Journal of Clinical Microbiology*, **2010**, 48, 52-6	9.7	136
158	In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial. *Journal of Clinical Microbiology*, **2010**, 48, 2613-4	9.7	2
157	In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2497-506	5.9	173

156	Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2655-9	5.9	102
155	Wide variability in the use of antimicrobial lock therapy and prophylaxis among infectious diseases consultants. *Infection Control and Hospital Epidemiology*, **2010**, 31, 554-7	2	9
154	Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. *Journal of Clinical Microbiology*, **2010**, 48, 1592-9	9.7	79
153	Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). *Journal of Clinical Microbiology*, **2010**, 48, 3251-7	9.7	194
152	Epidemiology of invasive mycoses in North America. *Critical Reviews in Microbiology*, **2010**, 36, 1-53	7.8	669
151	Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. *International Journal of Medical Microbiology*, **2010**, 300, 265-70	3.7	70
150	Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. *Diagnostic Microbiology and Infectious Disease*, **2010**, 67, 56-60	2.9	24
149	Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. *Diagnostic Microbiology and Infectious Disease*, **2010**, 67, 162-71	2.9	65
148	Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. *Drug Resistance Updates*, **2010**, 13, 180-95	23.2	226
147	To screen or not to screen for methicillin-resistant Staphylococcus aureus. *Journal of Clinical Microbiology*, **2010**, 48, 683-9	9.7	46
146	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. *Journal of Clinical Microbiology*, **2010**, 48, 1366-77	9.7	432
145	Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and Candida: Time for New Clinical Breakpoints?. *Current Fungal Infection Reports*, **2010**, 4, 168-174	1.4	11
144	Community-associated methicillin-resistant Staphylococcus aureus, Iowa, USA. *Emerging Infectious Diseases*, **2009**, 15, 1582-9	10.2	32
143	Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. *Journal of Antimicrobial Chemotherapy*, **2009**, 63, 427-37	5.1	176
142	Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. *Journal of Clinical Microbiology*, **2009**, 47, 3142-6	9.7	120
141	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. *Journal of Clinical Microbiology*, **2009**, 47, 117-23	9.7	144
140	Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. *Journal of Clinical Microbiology*, **2009**, 47, 242-4	9.7	33
139	Screening of a large global Aspergillus fumigatus species complex collection by using a species-specific microsphere-based Luminex assay. *Journal of Clinical Microbiology*, **2009**, 47, 4171-2	9.7	17

138	In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. *Journal of Clinical Microbiology*, **2009**, 47, 3170-7	9.7	94
137	Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. *Journal of Clinical Microbiology*, **2009**, 47, 3185-90	9.7	97
136	Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. *Journal of Clinical Microbiology*, **2009**, 47, 1216-7	9.7	76
135	In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. *Journal of Clinical Microbiology*, **2009**, 47, 3323-5	9.7	91
134	A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. *Diagnostic Microbiology and Infectious Disease*, **2009**, 63, 233-6	2.9	19
133	Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. *Diagnostic Microbiology and Infectious Disease*, **2009**, 64, 152-7	2.9	32
132	Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. *Diagnostic Microbiology and Infectious Disease*, **2009**, 65, 27-34	2.9	20
131	Adverse outcomes associated with Contact Precautions: a review of the literature. *American Journal of Infection Control*, **2009**, 37, 85-93	3.8	231
130	Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. *Journal of Clinical Microbiology*, **2009**, 47, 3797-804	9.7	97
129	Staphylococcus aureus nasal colonization and colonization or infection at other body sites in patients on a burn trauma unit. *Infection Control and Hospital Epidemiology*, **2009**, 30, 721-6	2	18
128	Methicillin-resistant Staphylococcus aureus (MRSA) strain ST398 is present in midwestern U.S. swine and swine workers. *PLoS ONE*, **2009**, 4, e4258	3.7	316
127	Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. *Journal of Clinical Microbiology*, **2008**, 46, 2659-64	9.7	145
126	Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. *Diagnostic Microbiology and Infectious Disease*, **2008**, 60, 273-7	2.9	61
125	Development of a prediction rule for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus carriage in a Veterans Affairs Medical Center population. *Infection Control and Hospital Epidemiology*, **2008**, 29, 969-71	2	16
124	Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 4175-7	5.9	35
123	Molecular phylogenetic analysis of a geographically and temporally matched set of Candida albicans isolates from humans and nonmigratory wildlife in central Illinois. *Eukaryotic Cell*, **2008**, 7, 1475-86		41
122	Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections. *Journal of Clinical Microbiology*, **2008**, 46, 374-6	9.7	68
121	Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. *Journal of Clinical Microbiology*, **2008**, 46, 551-9	9.7	55

120	Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. *Journal of Clinical Microbiology*, **2008**, 46, 842-9	9.7	84
119	Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. *Journal of Clinical Microbiology*, **2008**, 46, 515-21	9.7	159
118	Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. *Journal of Clinical Microbiology*, **2008**, 46, 2155-9	9.7	47
117	Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program. *Journal of Clinical Microbiology*, **2008**, 46, 3585-90	9.7	38
116	Preventing MRSA infections: finding it is not enough. *JAMA - Journal of the American Medical Association*, **2008**, 299, 1190-2	27.4	24
115	In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. *Journal of Clinical Microbiology*, **2008**, 46, 2568-72	9.7	112
114	In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 3497-503	5.9	112
113	In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 539-50	5.9	119
112	In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. *Journal of Clinical Microbiology*, **2008**, 46, 150-6	9.7	314
111	Strain-relatedness of methicillin-resistant Staphylococcus aureus isolates recovered from patients with repeated infection. *Clinical Infectious Diseases*, **2008**, 46, 1241-7	11.6	49
110	Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. *Journal of Clinical Microbiology*, **2008**, 46, 2620-9	9.7	212
109	Nonmenstrual toxic shock syndrome due to methicillin-resistant Staphylococcus aureus. *Obstetrics and Gynecology*, **2008**, 112, 933-8	4.9	5
108	An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. *Infection Control and Hospital Epidemiology*, **2007**, 28, 212-4	2	55
107	Look before you leap: active surveillance for multidrug-resistant organisms. *Clinical Infectious Diseases*, **2007**, 44, 1101-7	11.6	92
106	Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. *Journal of Clinical Microbiology*, **2007**, 45, 796-802	9.7	61
105	Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi. *Journal of Clinical Microbiology*, **2007**, 45, 1322-4	9.7	25
104	Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. *Journal of Clinical Microbiology*, **2007**, 45, 1735-45	9.7	241
103	Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. *Journal of Clinical Microbiology*, **2007**, 45, 3352-9	9.7	259

102	Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units. *Journal of Infectious Diseases*, **2007**, 195, 330-8	7	93
101	Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. *Journal of Clinical Microbiology*, **2007**, 45, 3522-8	9.7	95
100	Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole. *Journal of Clinical Microbiology*, **2007**, 45, 1974-7	9.7	24
99	Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods. *Journal of Clinical Microbiology*, **2007**, 45, 70-5	9.7	69
98	Analysis of ALS5 and ALS6 allelic variability in a geographically diverse collection of Candida albicans isolates. *Fungal Genetics and Biology*, **2007**, 44, 1298-309	3.9	37
97	Epidemiology of invasive candidiasis: a persistent public health problem. *Clinical Microbiology Reviews*, **2007**, 20, 133-63	34	2860
96	Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. *Journal of Clinical Microbiology*, **2006**, 44, 3578-82	9.7	72
95	Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. *Journal of Clinical Microbiology*, **2006**, 44, 3533-8	9.7	79
94	Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. *Journal of Clinical Microbiology*, **2006**, 44, 3551-6	9.7	132
93	Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. *Journal of Clinical Microbiology*, **2006**, 44, 324-6	9.7	76
92	Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. *Clinical Microbiology Reviews*, **2006**, 19, 435-47	34	227
91	In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. *Journal of Clinical Microbiology*, **2006**, 44, 760-3	9.7	147
90	Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. *Journal of Clinical Microbiology*, **2006**, 44, 819-26	9.7	207
89	Influenza vaccination rates, feedback and the Hawthorne effect. *Infection Control and Hospital Epidemiology*, **2006**, 27, 98-9	2	7
88	Risk factors for groin wound infection after femoral artery catheterization: a case-control study. *Infection Control and Hospital Epidemiology*, **2006**, 27, 34-7	2	4
87	Epidemiology of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a rural state. *Infection Control and Hospital Epidemiology*, **2006**, 27, 252-6	2	16
86	A multicenter intervention to prevent catheter-associated bloodstream infections. *Infection Control and Hospital Epidemiology*, **2006**, 27, 662-9	2	106
85	Descriptive epidemiology and case-control study of patients colonized with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus. *Infection Control and Hospital Epidemiology*, **2006**, 27, 913-9	2	9

84	Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals. *Infection Control and Hospital Epidemiology*, **2006**, 27, 1088-95	2	43
83	Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. *Diagnostic Microbiology and Infectious Disease*, **2006**, 55, 209-12	2.9	60
82	A case of recurrent episodes of Candida parapsilosis fungemia. *Mycopathologia*, **2006**, 162, 295-8	2.9	6
81	Implementation of strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in U.S. hospitals. *Infection Control and Hospital Epidemiology* , **2005**, 26, 21-30	2	17
80	Variation in the use of procedures to monitor antimicrobial resistance in U.S. hospitals. *Infection Control and Hospital Epidemiology*, **2005**, 26, 31-8	2	7
79	Importance of control group selection for evaluating antimicrobial use as a risk factor for methicillin-resistant Staphylococcus aureus bacteremia. *Infection Control and Hospital Epidemiology*, **2005**, 26, 634-7	2	13
78	Varying rates of Clostridium difficile-associated diarrhea at prevention epicenter hospitals. *Infection Control and Hospital Epidemiology*, **2005**, 26, 676-9	2	41
77	Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. *Journal of Clinical Microbiology*, **2005**, 43, 2155-62	9.7	298
76	Determining the clinical significance of coagulase-negative staphylococci isolated from blood cultures. *Infection Control and Hospital Epidemiology*, **2005**, 26, 559-66	2	122
75	In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. *Journal of Clinical Microbiology*, **2005**, 43, 3807-10	9.7	60
74	Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. *Journal of Clinical Microbiology*, **2005**, 43, 5208-13	9.7	45
73	Unusual fungal and pseudofungal infections of humans. *Journal of Clinical Microbiology*, **2005**, 43, 1495-504	9.7	59
72	Disk diffusion testing using Candida sp. colonies taken directly from CHROMagar Candida medium may decrease time required to obtain results. *Journal of Clinical Microbiology*, **2005**, 43, 3497-9	9.7	6
71	Activities of available and investigational antifungal agents against rhodotorula species. *Journal of Clinical Microbiology*, **2005**, 43, 476-8	9.7	93
70	Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. *Journal of Clinical Microbiology*, **2005**, 43, 5848-59	9.7	161
69	Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 4795-7	5.9	46
68	Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). *Journal of Clinical Microbiology*, **2005**, 43, 2163-7	9.7	162
67	In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. *Journal of Clinical Microbiology*, **2005**, 43, 5425-7	9.7	135

66	Enhanced identification of postoperative infections among inpatients. *Emerging Infectious Diseases*, **2004**, 10, 1924-30	10.2	100
65	Rapid detection of antimicrobial-resistant organism carriage: an unmet clinical need. *Journal of Clinical Microbiology*, **2004**, 42, 2879-83	9.7	50
64	Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. *Journal of Clinical Microbiology*, **2004**, 42, 3607-12	9.7	52
63	Accuracy and appropriateness of antimicrobial susceptibility test reporting for bacteria isolated from blood cultures. *Journal of Clinical Microbiology*, **2004**, 42, 2258-60	9.7	12
62	Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. *Journal of Clinical Microbiology*, **2004**, 42, 4977-9	9.7	43
61	Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. *Journal of Clinical Microbiology*, **2004**, 42, 3137-41	9.7	59
60	Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. *Journal of Clinical Microbiology*, **2004**, 42, 3142-6	9.7	139
59	Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole. *Journal of Clinical Microbiology*, **2004**, 42, 380-3	9.7	22
58	Stability of Mueller-Hinton agar supplemented with glucose and methylene blue for disk diffusion testing of fluconazole and voriconazole. *Journal of Clinical Microbiology*, **2004**, 42, 1288-9	9.7	15
57	Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. *Journal of Clinical Microbiology*, **2004**, 42, 3117-9	9.7	78
56	Antimicrobial resistance trends and outbreak frequency in United States hospitals. *Clinical Infectious Diseases*, **2004**, 38, 78-85	11.6	220
55	Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. *HIV Medicine*, **2004**, 5, 144-50	2.7	39
54	Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. *Clinical Infectious Diseases*, **2004**, 39, 584-7	11.6	255
53	Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. *Journal of Clinical Microbiology*, **2004**, 42, 4419-31	9.7	538
52	Nosocomial candidemia: an ounce of prevention is better than a pound of cure. *Infection Control and Hospital Epidemiology*, **2004**, 25, 624-6	2	43
51	In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. *Diagnostic Microbiology and Infectious Disease*, **2004**, 48, 201-5	2.9	198
50	In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. *Diagnostic Microbiology and Infectious Disease*, **2004**, 48, 101-5	2.9	76
49	Are United States hospitals following national guidelines for the analysis and presentation of cumulative antimicrobial susceptibility data?. *Diagnostic Microbiology and Infectious Disease*, **2004**, 49, 141-5	2.9	31

48	Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans. *Diagnostic Microbiology and Infectious Disease*, **2004**, 50, 113-7	2.9	10
47	Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. *Journal of Clinical Microbiology*, **2003**, 41, 1440-6	9.7	138
46	Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. *Journal of Clinical Microbiology*, **2003**, 41, 2176-9	9.7	86
45	Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans. *Journal of Clinical Microbiology*, **2003**, 41, 97-9	9.7	28
44	Prenatal testing for infectious disease. *Clinics in Laboratory Medicine*, **2003**, 23, 295-315, viii	2.1	3
43	Prevalence of the use of central venous access devices within and outside of the intensive care unit: results of a survey among hospitals in the prevention epicenter program of the Centers for Disease Control and Prevention. *Infection Control and Hospital Epidemiology*, **2003**, 24, 942-5	2	108
42	Caspofungin activity against clinical isolates of fluconazole-resistant Candida. *Journal of Clinical Microbiology*, **2003**, 41, 5729-31	9.7	96
41	In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 1068-71	5.9	138
40	In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. *Diagnostic Microbiology and Infectious Disease*, **2003**, 45, 241-4	2.9	38
39	Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. *Journal of Clinical Microbiology*, **2003**, 41, 3623-6	9.7	306
38	Epidemiology and outcome of nosocomial and community-onset bloodstream infection. *Journal of Clinical Microbiology*, **2003**, 41, 3655-60	9.7	211
37	Attributable mortality of nosocomial candidemia, revisited. *Clinical Infectious Diseases*, **2003**, 37, 1172-7	11.6	879
36	In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. *Journal of Clinical Microbiology*, **2003**, 41, 78-83	9.7	135
35	Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. *Journal of Clinical Microbiology*, **2003**, 41, 1087-90	9.7	39
34	Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci. *Journal of Clinical Microbiology*, **2003**, 41, 2659-61	9.7	41
33	Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. *Journal of Clinical Microbiology*, **2003**, 41, 1875-80	9.7	47
32	Fluoroquinolone resistance in Streptococcus pyogenes. *Clinical Infectious Diseases*, **2003**, 36, 380-3	11.6	32
31	Detection and treatment of bloodstream infection: laboratory reporting and antimicrobial management. *Journal of Clinical Microbiology*, **2003**, 41, 495-7	9.7	130

30	In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. *Journal of Clinical Microbiology*, **2003**, 41, 1126-9	9.7	65
29	Effects of rapid detection of bloodstream infections on length of hospitalization and hospital charges. *Journal of Clinical Microbiology*, **2003**, 41, 3119-25	9.7	144
28	Use of active surveillance cultures to control vancomycin-resistant Enterococcus. *Clinical Infectious Diseases*, **2003**, 37, 1400-2; author reply 1402-3	11.6	2
27	Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. *Journal of Clinical Microbiology*, **2002**, 40, 3551-7	9.7	207
26	In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 3518-21	5.9	100
25	Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. *Journal of Clinical Microbiology*, **2002**, 40, 1298-302	9.7	293
24	Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. *Journal of Clinical Microbiology*, **2002**, 40, 852-6	9.7	239
23	Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole. *Journal of Clinical Microbiology*, **2002**, 40, 1694-7	9.7	12
22	Minimizing the workup of blood culture contaminants: implementation and evaluation of a laboratory-based algorithm. *Journal of Clinical Microbiology*, **2002**, 40, 2437-44	9.7	105
21	Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000. *International Journal of Antimicrobial Agents*, **2002**, 20, 412-8	14.3	77
20	Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. *Clinical Microbiology and Infection*, **2001**, 7, 152-7	9.5	46
19	Comparison of the Vitek gram-positive susceptibility 106 card, the MRSA-Screen latex agglutination test, and mecA analysis for detecting oxacillin resistance in a geographically diverse collection of clinical isolates of coagulase-negative staphylococci. *Journal of Clinical Microbiology*, **2001**, 39, 3633-6	9.7	33
18	International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. *Journal of Clinical Microbiology*, **2001**, 39, 3254-9	9.7	419
17	Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. *Journal of Clinical Microbiology*, **2001**, 39, 2439-44	9.7	258
16	Comparison of the Vitek Gram-Positive Susceptibility 106 card and the MRSA-screen latex agglutination test for determining oxacillin resistance in clinical bloodstream isolates of Staphylococcus aureus. *Journal of Clinical Microbiology*, **2001**, 39, 53-6	9.7	40
15	Effect of coinfection with GB virus C on survival among patients with HIV infection. *New England Journal of Medicine*, **2001**, 345, 707-14	59.2	312
14	Surveillance of antibiotic resistance in European ICUs. *Journal of Hospital Infection*, **2001**, 48, 161-76	6.9	92
13	Oxazolidinone antibiotics. *Lancet, The*, **2001**, 358, 1975-82	40	297

12	Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. *American Journal of Obstetrics and Gynecology*, **2000**, 183, 859-62	6.4	90
11	Genetic relatedness of multidrug-resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY Antimicrobial Resistance Surveillance Centers worldwide, 1998. *Microbial Drug Resistance*, **2000**, 6, 213-21	2.9	43
10	Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. *International Journal of Antimicrobial Agents*, **2000**, 13, 257-71	14.3	102
9	Oxazolidinones: a review. *Drugs*, **2000**, 59, 7-16	12.1	157
8	Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae. *Emerging Infectious Diseases*, **2000**, 6, 552-6	10.2	69
7	Clinical impact of changing to an automated blood-culture system at a small community hospital. *Clinical Microbiology and Infection*, **1999**, 5, 590-593	9.5	1
6	Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers. *Diagnostic Microbiology and Infectious Disease*, **1999**, 34, 37-43	2.9	35
5	Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals. *Diagnostic Microbiology and Infectious Disease*, **1999**, 35, 81-8	2.9	21
4	An outbreak of Candida parapsilosis prosthetic valve endocarditis. *Diagnostic Microbiology and Infectious Disease*, **1997**, 29, 147-53	2.9	77
3	Blood and body fluid exposures during clinical training: relation to knowledge of universal precautions. *Journal of General Internal Medicine*, **1996**, 11, 109-11	4	19
2	Universal precautions training of preclinical students: impact on knowledge, attitudes, and compliance. *Preventive Medicine*, **1995**, 24, 580-5	4.3	30
1	Employee health and infection control. *Infection Control and Hospital Epidemiology*, **1995**, 16, 292-301	2	12